Security Snapshot

PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) Institutional Ownership

CUSIP: 74587V107

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

150

Shares (Excl. Options)

35,344,888

Price

$5.95

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
PBYI on Nasdaq
Shares outstanding
49,633,071
Price per share
$6.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
35,344,888
Total reported value
$210,232,618
% of total 13F portfolios
0%
Share change
+756,755
Value change
+$5,397,540
Number of holders
150
Price from insider filings
$6.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock is tracked under CUSIP 74587V107.
  • 150 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 150 to 62 between Q4 2025 and Q1 2026.
  • Reported value moved from $210,232,618 to $54,017,042.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 150 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 74587V107?
CUSIP 74587V107 identifies PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 8% +19% $11,859,557 +$1,988,442 3,940,052 +20% Anders Hove 31 Dec 2024
BlackRock, Inc. 5.6% $8,366,151 2,779,452 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.9% $5,701,319 1,894,126 Millennium Management LLC 31 Dec 2024

As of 31 Dec 2025, 150 institutional investors reported holding 35,344,888 shares of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI). This represents 71% of the company’s total 49,633,071 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ACORN CAPITAL ADVISORS, LLC 8.3% 4,131,299 0% 8.3% $24,581,229
VANGUARD GROUP INC 7.7% 3,797,748 +2.9% 0% $22,596,600
BlackRock, Inc. 7.3% 3,642,588 +1.8% 0% $21,673,399
RENAISSANCE TECHNOLOGIES LLC 4.3% 2,123,813 -1.3% 0.02% $12,636,687
ACADIAN ASSET MANAGEMENT LLC 4.1% 2,024,823 -1.4% 0.02% $12,043,000
AMERICAN CENTURY COMPANIES INC 3.3% 1,650,137 +11% 0% $9,818,315
DIMENSIONAL FUND ADVISORS LP 2.7% 1,339,603 +5.3% 0% $7,971,040
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 2.3% 1,120,329 +35% 0.04% $6,665,958
GEODE CAPITAL MANAGEMENT, LLC 2% 994,345 +1.1% 0% $5,917,285
STATE STREET CORP 1.8% 877,077 +17% 0% $5,218,608
Connor, Clark & Lunn Investment Management Ltd. 1.8% 875,301 -7.2% 0.01% $5,208,041
KENNEDY CAPITAL MANAGEMENT LLC 1.7% 868,315 +0.08% 0.11% $5,166,474
GOLDMAN SACHS GROUP INC 1.6% 793,962 +238% 0% $4,724,074
BRIDGEWAY CAPITAL MANAGEMENT, LLC 1.6% 773,485 +78% 0.1% $4,602,236
RITHOLTZ WEALTH MANAGEMENT 1.4% 694,001 +47% 0.08% $4,129,306
AQR CAPITAL MANAGEMENT LLC 1.3% 666,605 +410% 0% $3,966,300
NORTHERN TRUST CORP 1.2% 616,197 +17% 0% $3,666,372
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.1% 547,853 +18% 0% $3,259,725
GLOBEFLEX CAPITAL L P 0.91% 452,606 0% 0.41% $2,693,006
SEI INVESTMENTS CO 0.87% 429,925 +24% 0% $2,558,037
LSV ASSET MANAGEMENT 0.82% 404,802 -28% 0.01% $2,409,000
D. E. Shaw & Co., Inc. 0.76% 378,296 -24% 0% $2,250,861
Bank of New York Mellon Corp 0.71% 351,881 -0.98% 0% $2,093,693
MORGAN STANLEY 0.66% 326,774 -14% 0% $1,944,305
PRUDENTIAL FINANCIAL INC 0.58% 286,509 +30% 0% $1,704,729

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 8,455,158 $54,017,042 +$4,797,507 $6.39 62
2025 Q4 35,344,888 $210,232,618 +$5,397,540 $5.95 150
2025 Q3 34,380,273 $182,532,985 +$11,531,913 $5.31 131
2025 Q2 32,782,327 $112,437,236 +$8,596,760 $3.43 121
2025 Q1 30,413,709 $90,020,693 +$2,952,602 $2.96 116
2024 Q4 29,394,127 $89,648,308 -$7,801,084 $3.05 111
2024 Q3 29,741,414 $75,860,432 -$5,784,759 $2.55 100
2024 Q2 30,964,332 $100,942,686 -$1,236,662 $3.26 98
2024 Q1 29,743,016 $157,668,204 +$17,052,475 $5.30 93
2023 Q4 26,608,129 $115,214,198 +$4,767,738 $4.33 82
2023 Q3 25,704,166 $67,598,924 -$2,428,856 $2.63 67
2023 Q2 26,576,438 $93,807,644 -$4,382,380 $3.53 67
2023 Q1 27,855,345 $86,065,002 -$527,663 $3.09 77
2022 Q4 27,496,427 $116,318,396 -$138,759 $4.23 86
2022 Q3 27,643,484 $65,508,451 -$1,989,453 $2.37 71
2022 Q2 27,896,143 $79,494,556 -$4,139,901 $2.85 77
2022 Q1 29,904,506 $86,071,643 -$477,483 $2.88 95
2021 Q4 30,286,741 $92,179,926 -$39,504,988 $3.04 96
2021 Q3 32,161,600 $225,498,183 -$28,665,006 $7.01 112
2021 Q2 34,758,681 $319,233,355 -$17,282,962 $9.18 118
2021 Q1 36,622,682 $355,897,814 +$13,747,740 $9.72 117
2020 Q4 35,303,327 $362,460,750 -$9,270,334 $10.26 120
2020 Q3 38,674,035 $390,198,466 +$12,930,607 $10.09 128
2020 Q2 35,087,132 $365,869,787 -$6,707,284 $10.43 124
2020 Q1 36,622,300 $308,895,684 +$43,630,089 $8.44 121
2019 Q4 31,346,607 $274,240,276 -$64,624,795 $8.75 129
2019 Q3 36,566,451 $393,738,047 +$16,141,553 $10.77 138
2019 Q2 34,765,202 $441,844,355 -$103,904,681 $12.71 132
2019 Q1 34,161,633 $1,323,863,060 +$17,647,411 $38.79 156
2018 Q4 35,195,489 $716,303,054 -$227,829,815 $20.35 137
2018 Q3 35,649,697 $1,634,461,087 -$26,392,843 $45.85 154
2018 Q2 35,935,120 $2,125,191,869 -$1,056,901 $59.15 169
2018 Q1 35,574,353 $2,419,811,616 -$81,238,705 $68.05 168
2017 Q4 36,157,207 $3,573,656,170 -$112,228,539 $98.85 194
2017 Q3 36,681,359 $4,391,736,256 +$169,794,588 $119.75 170
2017 Q2 35,525,549 $3,104,620,640 +$57,539,772 $87.40 152
2017 Q1 37,964,211 $1,412,435,790 +$191,118,200 $37.20 135
2016 Q4 34,931,958 $1,072,410,439 +$72,943,477 $30.70 128
2016 Q3 29,992,904 $2,010,275,475 +$5,538,941 $67.05 145
2016 Q2 31,810,369 $947,699,404 +$39,640,223 $29.79 107
2016 Q1 30,412,423 $892,904,817 -$134,999,214 $29.37 114
2015 Q4 32,269,617 $2,529,775,949 +$177,573,758 $78.40 131
2015 Q3 30,151,475 $2,271,836,092 -$40,738,025 $75.36 159
2015 Q2 30,442,694 $3,553,611,040 -$40,063,235 $116.75 193
2015 Q1 29,120,599 $6,873,292,525 +$477,852,182 $236.11 194
2014 Q4 27,148,671 $5,140,326,488 +$68,524,432 $189.27 183
2014 Q3 26,680,747 $6,365,417,896 +$471,513,554 $238.57 182
2014 Q2 25,372,332 $1,674,353,490 -$43,122,202 $66.00 132
2014 Q1 25,068,536 $2,610,636,453 +$107,147,987 $104.14 130
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .